NXPH1 Human
Description
Product Specs
Product Science Overview
Neurexophilin 1 is characterized by its unique structure, which includes:
- N-terminal signal peptide: This segment directs the protein to the secretory pathway.
- Variable N-terminal domain: This domain varies among different neurexophilins.
- Highly conserved central domain: This domain is N-glycosylated, meaning it has sugar molecules attached to it.
- Short linker region: This region connects the central domain to the C-terminal domain.
- Cysteine-rich C-terminal domain: This domain is essential for the protein’s stability and function .
Neurexophilin 1 forms a tight complex with alpha-neurexins (α-neurexins), which are proteins that promote adhesion between dendrites and axons. This interaction is crucial for synaptic function and the formation of neural circuits . Neurexophilin 1 is physiologically processed in neuronal cells, where it undergoes N-glycosylation and proteolytic cleavage to form a mature protein .
Neurexophilin 1 is expressed in various tissues, including the brain, where it plays a role in synaptic signaling. The protein is rapidly N-glycosylated after synthesis and then slowly processed to a smaller mature form through endoproteolytic cleavage. This processing occurs specifically in neuron-like cells, indicating a cell-specific mechanism .
Recombinant Neurexophilin 1 is produced using genetic engineering techniques, where the NXPH1 gene is inserted into a host cell, such as bacteria or mammalian cells, to produce the protein. This recombinant protein is used in research to study its structure, function, and interactions with other proteins, such as neurexins .
Research on Neurexophilin 1 has provided insights into its role in the nervous system and its potential implications in neurological disorders. Studies have shown that Neurexophilin 1 can suppress the proliferation of hematopoietic cells, indicating its potential role in regulating cell growth and differentiation . Additionally, understanding the interaction between Neurexophilin 1 and neurexins can help in developing therapeutic strategies for synaptic dysfunction and related diseases .
